EDN1 and systemic sclerosis: It was demonstrated that ET-1 levels were reduced by bosentan treatment in SSc patients with PAH to the levels present in SSc patients without PAH, indicating that this biomarker could be an indicator of the severity of vascular damage and response to treatment.